NCT03712540 is a Phase 1 clinical trial of BMS-986278 in Healthy Participants, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03712540?

NCT03712540 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT03712540?

Interventions in NCT03712540: BMS-986278, Rifampin.

What condition does NCT03712540 study?

NCT03712540 studies Healthy Participants.

Is NCT03712540 still recruiting?

NCT03712540 is currently completed. Last updated 12 June 2019.

Last reviewed 2019-06-12 · How we verify

NCT03712540

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

Completed Phase 1 Last updated 12 June 2019

What this trial tests

Phase 1 trial testing BMS-986278 in Healthy Participants in 39 participants. Completed in 8 November 2018.

Timeline

6 September 2018

Primary endpoint
8 November 2018

8 November 2018

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	6 September 2018
Primary completion	8 November 2018
Estimated completion	8 November 2018
Sites	1 location across United States

Drugs / interventions tested

BMS-986278 — full drug profile →
Rifampin — full drug profile →

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 21 to 65, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effects of experimental medication BMS-986278 given with the antibiotic Rifampin in healthy participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Proceedings of the World Molecular Imaging Congress 2019, Montreal Quebec, Canada September 4-7, 2019: Late-Breaking Abstracts.
· 2019 · PMID 31745759 · DOI 10.1007/s11307-019-01453-z

Verify or expand the search:

Other trials of BMS-986278

Trials testing the same drug.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07422298 — A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants · Phase 1 · recruiting
NCT06746402 — A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Car · Phase 1 · completed
NCT06723535 — A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal D · Phase 1 · completed
NCT06425198 — Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of · Phase 1 · completed

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03712540 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 12 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03712540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing